Cardinal Health (CAH) has been consistently outperforming the market and seeing strong momentum in its stock. Investors have seen returns of up to
282% over the past five years, while including in the
Russell 1000 Index has given it a further boost. The healthcare logistics provider appears bullish on its prospects, citing expectations of
double-digit EPS growth amid a strong healthcare sector. Its third quarter results for fiscal year 2025 beat estimates while the
specialty drugs unit and updated long-term value creation plans have raised profit expectations. Strategic additions have been made to its portfolio, including
innovative medical devices and distribution services. Growth has also been seen in the cell and gene therapy industry. However, the recent layoffs due to tariff costs remain a concern. Despite some market fluctuations, CAH continues to receive strong ratings and reaffirmations of a 'buy' status.
Cardinal Health CAH News Analytics from Fri, 01 Nov 2024 07:00:00 GMT to Sat, 05 Jul 2025 12:33:39 GMT -
Rating 7
- Innovation -3
- Information 7
- Rumor -1